ER+ breast tumors classically require estrogen‐induced ER signaling for growth; however, clinical studies investigating estrogen therapies have demonstrated that tumors growing in low‐estrogen conditions may be growth‐inhibited by estrogen (Ellis et al., 2009). The gene discussed is ESR1; the disease is breast neoplasm.